Kaynak: Zacks Investment Research
Haber Ajansı
Hisse Senedi
Orta Önem

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.
İlgili Semboller
1
M
MRNA
MRNA
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et